ENABLE-2
About us
An interdisciplinary team of international experts guiding researchers with early-stage antibacterial programmes.
Current programmes
ENABLE-2 is currently supporting four promising programmes in the pursuit of new antibiotics.
News
Read the latest updates on programmes and progress from the antibacterial drug discovery platform ENABLE-2
ENABLE-2 Platform
The team progressing the ENABLE-2 programmes
Contact us
Contact the ENABLE-2 management team
Apply to ENABLE-2
We accept applications from researchers at European publicly-funded universities and research institutes.
ENABLE-2 Incubator
ENABLE-2 Incubator Hit validation evaluates the antibiotic potential of novel compounds
Hit to Lead programme
ENABLE-2 is set up with a strong focus on developing small molecule programmes in the Hit to Lead stage.
Welcome to ENABLE-2
ENABLE-2 is an antibacterial drug discovery platform with focus on the early stages of antibiotic discovery and development. ENABLE-2 supports the development of direct acting systemic antibacterial compounds to ensure a sustainable flow of new antibacterial drug candidates into the development pipeline.
ENABLE-2 is based on learnings from ENABLE (Innovative Medicines Initiative) and supported by the Swedish Research Council and the National Research Programme on Antibiotic Resistance.
